PDF
(Download)
|
- Bilberry (Vaccinium myrtillus)
- French Maritime Pine (Pinus pinaster)
- Glaucoma
| Date:
11-15-2010 | HC# 071053-412
|
Re: Bilberry Extract with Pycnogenol® Alleviates Intraocular Pressure Elevations and Improves Clinical Response to Local Medication for This Asymptomatic Condition
Steigerwalt RD, Belcaro G, Morazzoni P, Bombardelli E, Burki
C, Schönlau F. Mirtogenol® potentiates latanoprost in lowering
intraocular pressure and improves ocular blood flow in asymptomatic subjects. Clin Ophthalmol. May 2010;4:471-476.
Glaucoma is a leading cause of
blindness. In most types of glaucoma, fluid and pressure build up slowly inside
the eye. Excessively increased intraocular pressure damages the optic nerve,
which is the nerve that transmits information from the eye to the brain. A
previous exploratory pilot study found that a combination of extracts from bilberry
(Vaccinium myrtillus) and French
maritime pine (Pinus pinaster) bark
(Pycnogenol®; Horphag Research; Geneva, Switzerland) reduced intraocular
pressure and improved blood flow in the eye. The purpose of this open-label,
randomized trial was to evaluate the effects of Mirtogenol®, a
combination of bilberry extract and Pycnogenol, and the prescription drug
latanoprost on intraocular pressure and ocular blood flow in people diagnosed
with ocular hypertension.
The trial was conducted at the University of Chieti-Pescara,
San Valentino,
Italy. People
with asymptomatic intraocular hypertension (35-40 mmHg) who were free from
degenerative eye disorders, cardiovascular disease, and other systemic diseases
were enrolled in the trial. The subjects were randomly assigned to 1 of 3
groups for 24 weeks. The first group used 1 drop of latanoprost (Xalatan®;
Pharmacia Pfizer; New York, New York)
in each eye every evening. The second group took 1 tablet of Mirtogenol every
morning. One tablet of Mirtogenol contained 80 mg bilberry extract standardized
to 36% anthocyanins (Mirtoselect®; Indena S.p.A.; Milan, Italy) plus 40 mg French maritime
pine bark extract standardized to 70% procyanidins (Pycnogenol). The third
group used both latanoprost and Mirtogenol every day. Intraocular pressure and
blood flow velocity in the central retinal artery were measured on weeks 0, 4,
6, 12, 16, 20, and 24.
A total of 79 subjects were enrolled, and all subjects
completed the trial. The mean age in each group ranged from 48.6 to 49.0 years.
There were no significant differences in age, intraocular pressure levels, or
blood flow velocity among the 3 groups at the beginning of the study.
In the latanoprost group (n=29), intraocular pressure
decreased from 37.7 mmHg at baseline to 27.2 mmHg after 4 weeks (P < 0.05)
and remained at that level until 24 weeks. In the Mirtogenol group (n=23),
intraocular pressure decreased from 38.1 mmHg at baseline to 29.0 mmHg after 16
weeks (P < 0.05) with no further change by 24 weeks. In the combined Mirtogenol
plus latanoprost group (n=27), intraocular pressure decreased from 38.0 mmHg at
baseline to 27.3 mmHg after 4 weeks (P < 0.05), to 24.2 mmHg by 6 weeks, and
further to 23.0 mmHg after 24 weeks. At all time points, pressure was
significantly lower in the latanoprost group than the Mirtogenol group (P <
0.05). Ocular pressure was significantly lower when latanoprost and Mirtogenol
were combined than when either was used alone at 16, 20, and 24 weeks (P <
0.05).
Blood flow velocities in the retinal artery increased
gradually in all 3 groups. The improvements were similar in the Mirtogenol and
latanoprost groups, with a significant increase observed at 12 weeks compared
to baseline (both P < 0.05). Mirtogenol increased blood flow velocities
significantly over latanoprost at 6 weeks for systolic and at 24 weeks for
diastolic (P < 0.05 for both). The Mirtogenol plus latanoprost group had
significantly greater improvement in diastolic blood flow velocity than either
treatment by itself from 12 weeks to 24 weeks (P < 0.05). No adverse side
effects were reported in the Mirtogenol group. Blurred vision and eyelid or
conjunctival redness, which are known side effects of latanoprost, were
reported in both groups using latanoprost.
In this study, Mirtogenol lowered intraocular pressure and
increased retinal artery blood flow. Mirtogenol was almost as effective as
latanoprost, but the improvements were seen faster with latanoprost. The additive
effects of the combination of latanoprost and Mirtogenol suggest that they have
different pharmacologic actions. Bilberry extracts have been shown to modify the
capillaries in the ciliary body, which releases fluid within in the eye, and Pycnogenol
improves the function of the endothelial cells lining blood vessels and
capillaries. This suggests Mirtogenol may decrease fluid flow into the eye.
Latanoprost and similar prostaglandin F2a analogue drugs enhance fluid flow
out of the eye.
The authors conclude that Mirtogenol is safe and lowers
intraocular pressure in people with elevated intraocular pressure. While
Mirtogenol is not a replacement for latanoprost and similar drugs for the
treatment of glaucoma, it provides additional benefits when used in combination
with latanoprost. Mirtogenol may be useful in preventing an increase in ocular
hypertension, which would reduce the risk of developing glaucoma. Latanoprost
and other drugs are not suitable for prevention because of their potential for
serious side effects.
The authors mention a limitation of their study lay in the
measurement of blood velocity versus volume. In addition, another limitation of
the study is that the authors did not evaluate any systemic effects of
Mirtogenol. The advantage of ophthalmic medications is that there are no
systemic effects because the medication is given locally, and the concentration
is not high enough to produce systemic effects. In contrast, when a drug is
given systemically but the target is the eyes, the drug circulates through the
body and most likely produces not only ocular effects but also systemic
effects. Therefore, 6 months of treatment with Mirtogenol may be safe for the
eyes, but the systemic safety needs to be confirmed in these patients. Systemic
benefits may also accrue.
While the study confirms the findings of an earlier pilot
study, additional studies using larger numbers of subjects and longer treatment
duration should be conducted. This study adds to the growing evidence for
benefits of bilberry extracts and Pycnogenol in maintaining eye health.
–Heather S. Oliff,
PhD
|